Division of Organic Chemistry, CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pune 411 008, India.
Combichem Bio-resource Centre, CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pune 411 008, India.
Eur J Med Chem. 2017 Feb 15;127:459-469. doi: 10.1016/j.ejmech.2017.01.009. Epub 2017 Jan 9.
A number of hybrid molecules containing thienopyrimidinones and thiouracil moieties were designed, synthesized and tested against Mycobacterium tuberculosis H37Ra wherein it was observed that the compounds 11-14 exhibited antitubercular activity in vitro (MIC 7.6-19.1 μg/mL, 12-35 μM) against dormant stage while the compound 15 exhibited antitubercular activity in vitro against dormant (MIC 23.4 μg/mL, 41 μM) as well as active (MIC 25.4 μg/mL, 45 μM) stage. Structural modifications of the compound 15 were carried out to study the structure-activity relationship and it was observed that the compound 18 exhibited antitubercular activity comparable to the compound 15. Cytotoxicity studies revealed that these molecules were non-toxic. The docking study of the compound 15 showed that there was binding with the active site of mycobacterial pantothenate synthetase. Further docking studies led to the synthesis of the compounds 16 and 17 and the antitubercular activity screening results showed that these compounds have significant antitubercular activity. The compounds 15-18 (MIC 11-29 μg/mL, 19-51 μM) can be used as starting points for further optimization. The synthetic strategies used in the present work have potential to prepare a large number of compounds for further refinement of structures and the present results will be very useful in the development of a new class of antimycobacterial agents.
设计、合成并测试了一系列含有噻吩并嘧啶酮和硫尿嘧啶部分的杂化分子,观察到化合物 11-14 在体外对休眠期分枝杆菌 H37Ra 具有抗结核活性(MIC 7.6-19.1μg/mL,12-35μM),而化合物 15 在体外对休眠期(MIC 23.4μg/mL,41μM)和活性期(MIC 25.4μg/mL,45μM)均具有抗结核活性。对化合物 15 进行了结构修饰,以研究构效关系,观察到化合物 18 具有与化合物 15 相当的抗结核活性。细胞毒性研究表明这些分子没有毒性。化合物 15 的对接研究表明,它与分枝杆菌泛酸合酶的活性位点结合。进一步的对接研究导致了化合物 16 和 17 的合成,抗结核活性筛选结果表明这些化合物具有显著的抗结核活性。化合物 15-18(MIC 11-29μg/mL,19-51μM)可作为进一步优化的起点。本工作中使用的合成策略有潜力制备大量化合物,以进一步改进结构,目前的结果将非常有助于开发新类抗分枝杆菌药物。